GB201005740D0
|
|
A2b adenosine receptor antagonists
|
GB0911266D0
|
|
Therapeutic compounds
|
GB0905765D0
|
|
A2b adenosine receptor antagonists
|
GB0811850D0
|
|
Therapeutic compounds
|
GB0806532D0
|
|
A2b adenosine receptor antagonists
|
GB0711886D0
|
|
Therapeutic compounds
|
GB0705379D0
|
|
A2b adenosine receptor antagonists
|
GB0611498D0
|
|
Therapeutic compounds
|
GB0605861D0
|
|
A2B adenosine receptor antagonists
|
GB0510908D0
|
|
Therapeutic compounds
|
GB0510905D0
|
|
Therapeutic compounds
|
GB0505786D0
|
|
A2b adenosine receptor antagonists
|
US7414036B2
|
|
Compounds useful as A3 adenosine receptor agonists
|
GB0409267D0
|
|
Therapeutic compounds
|
GB0409277D0
|
|
Therapeutic compounds
|
GB0328295D0
|
|
Therapeutic compounds
|
WO03061670A1
|
|
Compounds useful as a3 adenosine receptor agonists
|
GB0212438D0
|
|
Compounds
|
GB0201919D0
|
|
A�-Adenosine receptor agonists
|
GB0201849D0
|
|
A�- adenosine receptor agonists
|